Concepedia

Author

Paulo Lúcio

Champalimaud FoundationORCID

Also Known As

P J Lúcio, P Lucio, P Lúcio, P. Lucio, P. Lúcio, PAULO LÚCIO, Paulo J. Lúcio, Paulo Lucio, Paulo Lúcio, Paulo Lúcio

75

Publications

4.3K

Citations

22

H-Index

40

Concepts

All Affiliations

Champalimaud FoundationMedical University of SilesiaNational and Kapodistrian University of AthensInstituto de Investigación Biomédica de SalamancaJanssen (United States)
PL

About

Paulo Lúcio is an author at Champalimaud Foundation specializing in hematology, medicine, and immunology.

Top Concepts

#ConceptH-IndexPublicationsCitations

1

Medicine

10

12

1.6K

2

Health Sciences

6

6

1.2K

3

Cell Biology

4

4

508

4

Engineering

1

1

137

5

Biostatistics

1

1

137

Paulo Lúcio

×

33

Publications

4.1K

Citations

21

H-Index

YearCitations

Daratumumab plus Bortezomib, Melphalan, and Prednisone for Untreated Myeloma

María‐Victoria Mateos, Meletios Α. Dimopoulos, Michèle Cavo,

New England Journal of Medicine

2017

949

EuroFlow antibody panels for standardized n-dimensional flow cytometric immunophenotyping of normal, reactive and malignant leukocytes

Jacques J. M. van Dongen, Ludovic Lhermitte, Sebastian Böttcher,

Leukemia

2012

893

Overall survival with daratumumab, bortezomib, melphalan, and prednisone in newly diagnosed multiple myeloma (ALCYONE): a randomised, open-label, phase 3 trial

María‐Victoria Mateos, Michèle Cavo, Joan Bladé,

The Lancet

2019

430

Pomalidomide, bortezomib, and dexamethasone for patients with relapsed or refractory multiple myeloma previously treated with lenalidomide (OPTIMISMM): a randomised, open-label, phase 3 trial

Paul G. Richardson, Albert Oriol, Meral Beksaç,

The Lancet Oncology

2019

375

Flow cytometric analysis of normal B cell differentiation: a frame of reference for the detection of minimal residual disease in precursor-B-ALL

Paulo Lúcio, A Parreira, MWM van den Beemd,

Leukemia

1999

234

BIOMED-1 concerted action report: flow cytometric immunophenotyping of precursor B-ALL with standardized triple-stainings

Paulo Lúcio, Giuseppe Gaipa, EG van Lochem,

Leukemia

2001

138

Quality assessment program for<scp>E</scp>uro<scp>F</scp>low protocols: Summary results of four‐year (2010–2013) quality assurance rounds

Tomáš Kalina, Juan Flores‐Montero, Quentin Lécrevisse,

Cytometry Part A

2014

137

Incidence and characteristics of CD4(+)/HLA DRhi dendritic cell malignancies.

Clara Bueno, Júlia Almeida, Paulo Lúcio,

PubMed

2004

123

Clinically useful information provided by the flow cytometric immunophenotyping of hematological malignancies: current status and future directions.

Alberto Orfao, Gerd Schmitz, Bruno Brando,

PubMed

1999

122

BIOMED-1 Concerted Action report: Flow cytometric characterization of CD7+ cell subsets in normal bone marrow as a basis for the diagnosis and follow-up of T cell acute lymphoblastic leukemia (T-ALL)

Anna Porwit‐MacDonald, E. Björklund, Paulo Lúcio,

Leukemia

2000

119

Page 1